Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

OncoAlert and ecancer weekly round up for July 12- July 18, 2021

Published: 19 Jul 2021

Views: 780

Rating:

Save

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of July 12- 18, 2021.

He highlights the KEYNOTE-522 trial where the addition of pembrolizumab to neoadjuvant chemotherapy has shown an EFS benefit in patients with early triple-negative breast cancer.

Alerts this week cover papers from The Breast, Lancet Oncology and Gut.

You can watch Dr Morgan's previous roundup here.

Follow Dr Morgan on twitter: @OncoAlert

Follow ecancer on twitter: @ecancer

Related Videos

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Lenvatinib plus pembrolizumab versus standard of care for previously treated...

Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan

Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer ( Dr Akihito Kawazoe - National Cancer Center Hospital East, Kashiwa, Japan )

Erdafitinib and current treatment landscape for advanced bladder cancer

Dr Yohann Loriot and Prof Arlene Siefker-Radtke

Erdafitinib and current treatment landscape for advanced bladder cancer ( Dr Yohann Loriot and Prof Arlene Siefker-Radtke )

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG

Dr Roger Li - Moffitt Cancer Center, Tampa, USA

CG0070 plus pembro shows promising efficacy in NMIBC unresponsive to BCG ( Dr Roger Li - Moffitt Cancer Center, Tampa, USA )

Impact of BRAF-V600E mutation on the tumour microenvironment and associated...

Dr Mohamed Salem - Levine Cancer Institute, Charlotte, USA

Impact of BRAF-V600E mutation on the tumour microenvironment and associated genomic alterations in colorectal cancer ( Dr Mohamed Salem - Levine Cancer Institute, Charlotte, USA )

Breast cancer and survivorship

Dr. Ashwin Mehta - Memorial Healthcare System, Florida, USA

Breast cancer and survivorship ( Dr. Ashwin Mehta - Memorial Healthcare System, Florida, USA )

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial...

Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )

More from ecancer